2-pyridin-4-yl-5,6,7,8,9,10-hexahydro-11-thia-1,3-diazacycloocta[a]inden-4-ol | 1438886-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-pyridin-4-yl-5,6,7,8,9,10-hexahydro-11-thia-1,3-diazacycloocta[a]inden-4-ol
• 英文别名: 5-Pyridin-4-yl-8-thia-4,6-diazatricyclo[7.6.0.02,7]pentadeca-1(9),2(7),5-trien-3-one；5-pyridin-4-yl-8-thia-4,6-diazatricyclo[7.6.0.02,7]pentadeca-1(9),2(7),5-trien-3-one
• CAS: 1438886-97-5
• 化学式: C₁₇H₁₇N₃OS
• 分子量: 311.407
• InChiKey: QYYCMPMKLOCUIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  82.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-pyridin-4-yl-5,6,7,8,9,10-hexahydro-11-thia-1,3-diazacycloocta[a]inden-4-ol 在 三氯氧磷 作用下， 反应 1.0h， 以65%的产率得到4-chloro-2-(4-pyridyl)-5,6,7,8,9,10-hexahydrocycloocta[4,5]thieno[2,3-d]pyrimidine
  参考文献：
  名称：

  Synthesis and anticancer activity of novel 2-pyridyl hexahyrocyclooctathieno[2,3-d]pyrimidine derivatives

  摘要：

  A series of new 2-pyridyl hexahydrocycloocta [4,5]thieno[2,3-d]pyrimidines with different substituents as C-4 position was synthesized. The anticancer activity of the newly synthesized compounds was tested in vitro using a two-stage process utilizing 60 different human tumor cell lines representing leukemia, melanoma and cancers of lung, colon, central nervous system, ovary, kidney, prostate as well as breast. Compounds 4a, 6a, 7a, 7d and 7g showed potent anticancer activity at low concentrations against most of the used human tumor cell lines comparable with doxorubicin as standard potent anticancer drug (average log(10) GI(50) over all cell lines = -6.85). Also, compound 4b was selective against SNB-75 (CNS cancer) log(10) GI(50) = -5.57. Interestingly, compound 7e exhibited promising selectivity against 13 tumor cell lines showing growth inhibition percentages between 54.05 and 89.23. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.02.011
• 作为产物：
  描述：

  α-cyano-α-cyclooctylideneacetamide 在 盐酸 、 sulfur 、 二乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 2-pyridin-4-yl-5,6,7,8,9,10-hexahydro-11-thia-1,3-diazacycloocta[a]inden-4-ol
  参考文献：
  名称：

  Synthesis and anticancer activity of novel 2-pyridyl hexahyrocyclooctathieno[2,3-d]pyrimidine derivatives

  摘要：

  A series of new 2-pyridyl hexahydrocycloocta [4,5]thieno[2,3-d]pyrimidines with different substituents as C-4 position was synthesized. The anticancer activity of the newly synthesized compounds was tested in vitro using a two-stage process utilizing 60 different human tumor cell lines representing leukemia, melanoma and cancers of lung, colon, central nervous system, ovary, kidney, prostate as well as breast. Compounds 4a, 6a, 7a, 7d and 7g showed potent anticancer activity at low concentrations against most of the used human tumor cell lines comparable with doxorubicin as standard potent anticancer drug (average log(10) GI(50) over all cell lines = -6.85). Also, compound 4b was selective against SNB-75 (CNS cancer) log(10) GI(50) = -5.57. Interestingly, compound 7e exhibited promising selectivity against 13 tumor cell lines showing growth inhibition percentages between 54.05 and 89.23. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.02.011

文献信息

• [EN] THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C<br/>[FR] INHIBITEURS DE TYPE THIÉNOPYRIMIDINE DE PROTÉINES KINASES C ATYPIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2013078126A1

  公开（公告）日：2013-05-30

  The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X如本文所定义。式（I）的化合物及其盐具有PKC抑制活性，并可用于治疗增生性疾病。
• Thienopyrimidine Inhibitors of Atypical Protein Kinase C
  申请人：Cancer Research Technology Limited

  公开号：US20140323435A1

  公开（公告）日：2014-10-30

  The present application provides a compound of formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

  本申请提供了公式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X的定义如本文所述。公式（I）的化合物及其盐具有aPKC抑制活性，可用于治疗增殖性疾病。
• THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C
  申请人：Cancer Research Technology Limited

  公开号：EP3048106A1

  公开（公告）日：2016-07-27

  The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. The compound of formula (I) and its salts has aPKC inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式 (I) 的化合物 或其盐，其中 R1、R2、R3、R4、R5、R6、A、G、M、Q 和 X 如本文所定义。式（I）化合物及其盐具有 PKC 抑制活性，可用于治疗增殖性疾病。
• Thienopyrimidine inhibitors of atypical protein kinase C
  申请人：Cancer Research Technology Limited

  公开号：US10183950B2

  公开（公告）日：2019-01-22

  The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

  本申请提供了一种式 (I) 的化合物 或其盐，其中 R1、R2、R3、R4、R5、R6、A、G、M、Q 和 X 如本文所定义。式（I）化合物及其盐具有 PKC 抑制活性，可用于治疗增殖性疾病。
• EP2782917A1
  申请人：——

  公开号：EP2782917A1

  公开（公告）日：2014-10-01